Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities

Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, are complex and heterogeneous diseases characterized by a multifactorial etiology, therefore demanding a multimodal approach to disentangle the main pathophysiological components driving disease onset and progression. Adoption of a systems biology approach is increasingly advocated with the advent of multiomics profiling technologies, aiming to improve disease classification, to identify disease biomarkers, and to accelerate drug discovery for patients with IBD. However, clinical translation of multiomics-derived biomarker signatures is lagging behind because there are several obstacles that need to be addressed to realize clinically useful signatures. Multiomics integration and IBD-specific identification of molecular networks, standardization and clearly defined outcomes, strategies to tackle cohort heterogeneity, and external validation of multiomics-based signatures are critical aspects. While striving for personalized medicine in IBD, careful consideration of these aspects is, however, needed to adequately match biomarker targets (e.g., the gut microbiome, immunity, or oxidative stress) with their corresponding utilities (e.g., early disease detection and endoscopic and clinical outcome). Theory-driven disease classifications and predictions are still governing clinical practice, while this could be improved by adopting an unbiased, data-driven approach relying on molecular data structures integrated with patient and disease characteristics. In the foreseeable future, the main challenge will lie in the complexity and impracticality of implementing multiomics-based signatures into clinical practice. Still, this could be achieved by developing easy-to-use, robust, and cost-effective tools incorporating omics-derived predictive signatures and through the design and execution of prospective, longitudinal, biomarker-stratified clinical trials.

[1]  E. Villablanca,et al.  Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? , 2022, Nature Reviews Gastroenterology & Hepatology.

[2]  S. Vermeire,et al.  Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All , 2022, Journal of Crohn's & colitis.

[3]  S. Vermeire,et al.  Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises , 2022, Current research in pharmacology and drug discovery.

[4]  Minhu Chen,et al.  Precision medicine in IBD: genes, drugs, bugs and omics , 2021, Nature Reviews Gastroenterology & Hepatology.

[5]  L. Joosten,et al.  The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease , 2021, Journal of Crohn's & colitis.

[6]  D. Plichta,et al.  Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. , 2021, Cell host & microbe.

[7]  M. Dubinsky,et al.  Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease. , 2021, Journal of Crohn's & colitis.

[8]  D. Iliopoulos,et al.  IBD Systems Biology Is Here to Stay. , 2021, Inflammatory bowel diseases.

[9]  S. Ng,et al.  Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. , 2021, Gastroenterology.

[10]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[11]  S. Vermeire,et al.  Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis , 2020, Inflammatory bowel diseases.

[12]  Chava L. Ramspek,et al.  External validation of prognostic models: what, why, how, when and where? , 2020, Clinical kidney journal.

[13]  M. Schloter,et al.  Integrated microbiota and metabolite profiles link Crohn’s disease to sulfur metabolism , 2020, Nature Communications.

[14]  Jack M. Fu,et al.  Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD , 2020, Gut.

[15]  P. Lanting,et al.  Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.

[16]  L. Revilla Sancho,et al.  Multi-omic modelling of inflammatory bowel disease with regularized canonical correlation analysis , 2020, medRxiv.

[17]  M. Ferrante,et al.  Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. , 2020, The American journal of gastroenterology.

[18]  Padhmanand Sudhakar,et al.  Big data in IBD: big progress for clinical practice , 2020, Gut.

[19]  D. Plichta,et al.  Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. , 2020, Inflammatory bowel diseases.

[20]  M. Macoritto,et al.  Integrative Analysis of Transcriptomic and Proteomic Profiling in Inflammatory Bowel Disease Colon Biopsies. , 2019, Inflammatory bowel diseases.

[21]  M van Smeden,et al.  Changing predictor measurement procedures affected the performance of prediction models in clinical examples. , 2019, Journal of clinical epidemiology.

[22]  B. Alizadeh,et al.  Nutritional Assessment in Inflammatory Bowel Disease (IBD)—Development of the Groningen IBD Nutritional Questionnaires (GINQ) , 2019, Nutrients.

[23]  P. Rutgeerts,et al.  Effects of Ustekinumab on Histologic Disease Activity in Patients with Crohn's Disease. , 2019, Gastroenterology.

[24]  G. D'Haens,et al.  Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review , 2019, Journal of Crohn's & colitis.

[25]  D. Haller,et al.  Multi-omics in IBD biomarker discovery: the missing links , 2019, Nature Reviews Gastroenterology & Hepatology.

[26]  Kevin S. Bonham,et al.  Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases , 2019, Nature.

[27]  Kenneth G. C. Smith,et al.  A blood-based prognostic biomarker in IBD , 2019, Gut.

[28]  J Jack Lee,et al.  Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.

[29]  J. Stelling,et al.  Microbial network disturbances in relapsing refractory Crohn’s disease , 2019, Nature Medicine.

[30]  G. Collins,et al.  PROBAST : A Tool to Assess the Risk of Bias and Applicability of PredictionModel Studies , 2018 .

[31]  Kenneth G. C. Smith,et al.  PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial , 2018, BMJ Open.

[32]  C. Huttenhower,et al.  Gut microbiome structure and metabolic activity in inflammatory bowel disease , 2018, Nature Microbiology.

[33]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[34]  B. Alizadeh,et al.  Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ) , 2018, Journal of Gastroenterology.

[35]  R. Xavier,et al.  Multiomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease. , 2018, Gastroenterology.

[36]  Richard Hansen,et al.  Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn’s disease , 2018, Microbiome.

[37]  F. Baribaud Molecular surrogates of histologic activity in Crohn′s disease , 2017 .

[38]  D. Iliopoulos,et al.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy , 2017, Nature Reviews Gastroenterology & Hepatology.

[39]  Huyuan Yang,et al.  Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease , 2017, Journal of Crohn's & colitis.

[40]  Richard D Riley,et al.  External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges , 2016, BMJ.

[41]  L. Peyrin-Biroulet,et al.  Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease , 2016, Expert review of gastroenterology & hepatology.

[42]  E. Seidman,et al.  Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease , 2016, Therapeutic advances in gastroenterology.

[43]  H. Clevers,et al.  Reparative inflammation takes charge of tissue regeneration , 2016, Nature.

[44]  Gary S Collins,et al.  Sample size considerations for the external validation of a multivariable prognostic model: a resampling study , 2015, Statistics in medicine.

[45]  G. D'Haens,et al.  Assessment of mucosal healing in inflammatory bowel disease: review. , 2015, Gastrointestinal endoscopy.

[46]  Karel G M Moons,et al.  A new framework to enhance the interpretation of external validation studies of clinical prediction models. , 2015, Journal of clinical epidemiology.

[47]  P. Austin,et al.  Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models , 2014, Statistical methods in medical research.

[48]  A. Stensballe,et al.  Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. , 2014, World journal of gastroenterology.

[49]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[50]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[51]  Patrick Royston,et al.  The cost of dichotomising continuous variables , 2006, BMJ : British Medical Journal.

[52]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[53]  D. Iliopoulos,et al.  Environmental triggers in IBD: a review of progress and evidence , 2018, Nature Reviews Gastroenterology & Hepatology.

[54]  Valerii Fedorov,et al.  Consequences of dichotomization , 2009, Pharmaceutical statistics.

[55]  T. Ideker,et al.  A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.